Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-12T21:11:45.250Z Has data issue: false hasContentIssue false
  • English
  • Français

Conflict of Interest: A Japanese Perspective

Published online by Cambridge University Press:  22 June 2005

AKIRA AKABAYASHI ,
BRIAN TAYLOR SLINGSBY  and
YOSHIYUKI TAKIMOTO
AKIRA AKABAYASHI
Affiliation:
The Department of Biomedical Ethics at the School of Health Science and Nursing, University of Tokyo Graduate School of Medicine, Tokyo, Japan, and the University of Tokyo
BRIAN TAYLOR SLINGSBY
Affiliation:
The Graduate School of Medicine at the University of Tokyo, Japan
YOSHIYUKI TAKIMOTO
Affiliation:
The Center for Biomedical Ethics and Law at the University of Tokyo Graduate School of Medicine, Japan
Get access Rights & Permissions [Opens in a new window]

Extract

Until recently, many of Japan's medical and bioethical communities had ignored the issue of conflicts of interest (CIs). This is no longer the case. Discussion on the economic and ethical problems defined by CIs is now apparent in academic, political, and even industrial spheres. In June 2004, this debate was sparked by a scandal involving AnGes MG, Inc., a bioventure company set up by a faculty member at Osaka University Graduate School of Medicine. AnGes MG developed a gene therapy using the Hepatic Growth Factor for obstructive blood vessel disease. Japanese newspapers reported that “several physicians involved with clinical trials for AnGes obtained unlisted shares of stock. One physician allegedly received 32 million yen (U.S. $320,000) after AnGes MG went public on the ‘Mothers’ stock exchange” (a market for high-growth and emerging stocks).

Type
SPECIAL SECTION: INTERNATIONAL VOICES
Information
Cambridge Quarterly of Healthcare Ethics , Volume 14 , Issue 3 , July 2005 , pp. 277 - 280
Copyright
© 2005 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)